Condition or disease | Intervention/treatment |
---|---|
Prosthetic Joint Infection | Diagnostic Test: Calprotectin test |
Calprotectin is a biomarker closely associated with leucocytes in general, and is present in high volumes in neutrophil cells. Calprotectin is also produced by infiltrating monocytes and macrophages, where calprotectin is released upon phagocytosis. In neutrophils, calprotectin is stored intracellularly and are released upon activation of the cell. The determination of number of neutrophils and proportion of neutrophils out of total number of inflammatory cells is a diagnostic strategy commonly used in diagnosis of infection. Upon encounter with a pathogen, neutrophils have several strategies to fight infections , and produce high-levels of calprotectin. Activation of neutrophils, and release of calprotectin, can be for any reason causing activation of the complement system and aseptic Inflammatory responses. Moreover, Calprotectin is a danger associated molecular patterns (DAMP) signal influencing the inflammatory responses. The level of activated neutrophils in PJI provide basis of the presence of calprotectin in the synovial fluid of PJI patients, and thus, for calprotectin as a potential biomarker for PJI. Calprotectin-levels in the synovial fluid do not merely reflect the level of leucocytes and neutrophils present in the synovial fluid, but levels are correlated to the WBC content. Calprotectin is likely to reflect the number of activated cells and surpass the diagnostic accuracy of total WBC counts and neutrophil percentage for PJI diagnosis.
A level of calprotectin of 50 mg/L in the synovial fluid has very good diagnostic accuracy for PJI, supported by area under the curve values of more than 0.9. In a subgroup analysis for patients with chronic PJI, a NPV of 97% was observed. The excellent NPV may assist in the orthopaedic clinic to rule out the presence of infection and consider diagnostic alternatives for aseptic loosening and pain revision of the joint patient. A rapid and accurate distinction between these two causes is important as PJI and aseptic loosening are managed differently with regards to surgical Intervention and followup.
Point of Care Test diagnostics by lateral flow devices provides reliable test results within minutes of sample collection. Currently, Calprotectin can be detected by such lateral flow devices (developed by Orthogenics, Tromsø, Norway). The speed and ease of use of this test allows for diagnosis at patient's bed side. These tests can be applied in the physician's office, operating room, an ambulance, the home, the field, or in the hospital. As the results are timely they allow rapid diagnostic and identifies treatment alternatives for the patient. This technology empowers clinicians to make decisions at the "point-of-care" and can have significant impact on health care delivery and ability to address challenges of health disparities. However, it is important to validate the diagnostic utility of calprotectin POC in a diverse set of patients undergoing revision arthroplasty.
Study Type : | Observational |
Actual Enrollment : | 156 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Diagnostic Utility of a Novel Point-of-Care Test of Calprotectin for Revision Total |
Actual Study Start Date : | October 29, 2018 |
Actual Primary Completion Date : | January 7, 2020 |
Actual Study Completion Date : | March 4, 2020 |
Group/Cohort | Intervention/treatment |
---|---|
Primary total knee arthroplasty
Primary TKA patients included in the study, to provide a baseline level for calprotectin.
|
Diagnostic Test: Calprotectin test
Calprotectin will be measured both by ELISA and point of care test.
|
Aseptic revision total knee arthroplasty
Aseptic revision TKA patients included in the study. These are patients who are not considered infected according to Musculoskeletal Infection Society criteria for infection.
|
Diagnostic Test: Calprotectin test
Calprotectin will be measured both by ELISA and point of care test.
|
Revision septic total knee arthroplasty
Septic revision TKA patients included in the study. These are patients who are considered infected according to Musculoskeletal Infection Society criteria for infection.
|
Diagnostic Test: Calprotectin test
Calprotectin will be measured both by ELISA and point of care test.
|
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Three groups:
Primary total knee arthroplasty Aseptic revision total knee arthroplasty Septic revision total knee arthroplasty
Inclusion Criteria:
Exclusion Criteria:
United States, Florida | |
Cleveland Clinic Florida | |
Weston, Florida, United States, 33331 | |
United States, Ohio | |
Cleveland Clinic | |
Cleveland, Ohio, United States, 44195 |
Principal Investigator: | Carlos Higuera, MD | The Cleveland Clinic |
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date | October 2, 2018 | ||||
First Posted Date | October 3, 2018 | ||||
Results First Submitted Date | June 8, 2020 | ||||
Results First Posted Date | December 17, 2020 | ||||
Last Update Posted Date | December 17, 2020 | ||||
Actual Study Start Date | October 29, 2018 | ||||
Actual Primary Completion Date | January 7, 2020 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures |
Calprotectin POC [ Time Frame: Day of surgery ] lateral flow point of care test
|
||||
Original Primary Outcome Measures |
Calprotectin POC [ Time Frame: Day of surgery ] Point of care test
|
||||
Change History | |||||
Current Secondary Outcome Measures |
Calprotectin ELISA [ Time Frame: Day of surgery ] ELISA analysis
|
||||
Original Secondary Outcome Measures | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title | Diagnostic Utility of a Novel Point-of-Care Test of Calprotectin for Revision Total Knee Arthroplasty | ||||
Official Title | Diagnostic Utility of a Novel Point-of-Care Test of Calprotectin for Revision Total | ||||
Brief Summary | The purpose of this study is to investigate whether there are quantifiable differences in the level of calprotectin in the synovial fluid that allow separation of different modes of joint implant failure (e.g. infected, aseptic loosening). A subset of primary TKA patients (with history of OA) will be included as a baseline. | ||||
Detailed Description |
Calprotectin is a biomarker closely associated with leucocytes in general, and is present in high volumes in neutrophil cells. Calprotectin is also produced by infiltrating monocytes and macrophages, where calprotectin is released upon phagocytosis. In neutrophils, calprotectin is stored intracellularly and are released upon activation of the cell. The determination of number of neutrophils and proportion of neutrophils out of total number of inflammatory cells is a diagnostic strategy commonly used in diagnosis of infection. Upon encounter with a pathogen, neutrophils have several strategies to fight infections , and produce high-levels of calprotectin. Activation of neutrophils, and release of calprotectin, can be for any reason causing activation of the complement system and aseptic Inflammatory responses. Moreover, Calprotectin is a danger associated molecular patterns (DAMP) signal influencing the inflammatory responses. The level of activated neutrophils in PJI provide basis of the presence of calprotectin in the synovial fluid of PJI patients, and thus, for calprotectin as a potential biomarker for PJI. Calprotectin-levels in the synovial fluid do not merely reflect the level of leucocytes and neutrophils present in the synovial fluid, but levels are correlated to the WBC content. Calprotectin is likely to reflect the number of activated cells and surpass the diagnostic accuracy of total WBC counts and neutrophil percentage for PJI diagnosis. A level of calprotectin of 50 mg/L in the synovial fluid has very good diagnostic accuracy for PJI, supported by area under the curve values of more than 0.9. In a subgroup analysis for patients with chronic PJI, a NPV of 97% was observed. The excellent NPV may assist in the orthopaedic clinic to rule out the presence of infection and consider diagnostic alternatives for aseptic loosening and pain revision of the joint patient. A rapid and accurate distinction between these two causes is important as PJI and aseptic loosening are managed differently with regards to surgical Intervention and followup. Point of Care Test diagnostics by lateral flow devices provides reliable test results within minutes of sample collection. Currently, Calprotectin can be detected by such lateral flow devices (developed by Orthogenics, Tromsø, Norway). The speed and ease of use of this test allows for diagnosis at patient's bed side. These tests can be applied in the physician's office, operating room, an ambulance, the home, the field, or in the hospital. As the results are timely they allow rapid diagnostic and identifies treatment alternatives for the patient. This technology empowers clinicians to make decisions at the "point-of-care" and can have significant impact on health care delivery and ability to address challenges of health disparities. However, it is important to validate the diagnostic utility of calprotectin POC in a diverse set of patients undergoing revision arthroplasty. |
||||
Study Type | Observational | ||||
Study Design | Observational Model: Case-Control Time Perspective: Prospective |
||||
Target Follow-Up Duration | Not Provided | ||||
Biospecimen | Not Provided | ||||
Sampling Method | Non-Probability Sample | ||||
Study Population |
Three groups: Primary total knee arthroplasty Aseptic revision total knee arthroplasty Septic revision total knee arthroplasty |
||||
Condition | Prosthetic Joint Infection | ||||
Intervention | Diagnostic Test: Calprotectin test
Calprotectin will be measured both by ELISA and point of care test.
|
||||
Study Groups/Cohorts |
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status | Completed | ||||
Actual Enrollment |
156 | ||||
Original Estimated Enrollment |
150 | ||||
Actual Study Completion Date | March 4, 2020 | ||||
Actual Primary Completion Date | January 7, 2020 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria |
Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender |
|
||||
Ages | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers | No | ||||
Contacts | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries | United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number | NCT03694925 | ||||
Other Study ID Numbers | 18-882 | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement |
|
||||
Responsible Party | Carlos Higuera-Rueda, The Cleveland Clinic | ||||
Study Sponsor | The Cleveland Clinic | ||||
Collaborators | Not Provided | ||||
Investigators |
|
||||
PRS Account | The Cleveland Clinic | ||||
Verification Date | November 2020 |